Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

They can be associated with a range of medical conditions and medications that can also increase the risk of early death ...

The term sheet was signed in the presence of senior officials from BIRAC, the department of biotechnology, and industry ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.

Americans taking Ozempic could be at risk of deadly heat stroke amid soaring temperatures, experts warn. The warning comes as ...